

# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

NCT06850922

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1, Phase 2
<b>Sponsor</b>	Genentech, Inc.
<b>Enrollment</b>	546 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Documented diagnosis of diabetes mellitus (DM) (Type 1 or Type 2) with glycated hemoglobin (HbA1c)  $\leq$  12%
- Macular thickening secondary to DME involving the center of the fovea  $>$  325 microns
- Decreased VA attributable primarily to DME between 25 and 73 ETDRS letters

### Exclusion (8)

- Currently untreated DM or previously untreated participants who initiated oral anti-diabetic medication or insulin within 90 days prior to Day 1
  - Uncontrolled blood pressure (BP)
  - Pregnancy or breastfeeding, or intention to become pregnant during the study
  - For Parts 1-4: IVT anti-VEGF treatment within 90 days prior to Day 1; For Part 5: IVT anti-VEGF treatment within 120 days prior to Day 1 or IVT anti-VEGF treatment prior to Day 1 for treatment naïve participants
  - Treatment with SUSVIMOTM (ranibizumab injection) prior to Day 1
- ... and 3 more (see full listing online)

## Locations (78 total)

---

Barnet Dulaney Perkins Eye Center, Phoenix, Arizona, United States  
Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States  
Associated Retinal Consultants PC, Phoenix, Arizona, United States  
... and 75 more locations